510 related articles for article (PubMed ID: 18669587)
1. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
[TBL] [Abstract][Full Text] [Related]
2. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
Park SH; Kim DH; Kim D; Kim DH; Jung HC; Pan JG; Ahn T; Kim D; Yun CH
Drug Metab Dispos; 2010 May; 38(5):732-9. PubMed ID: 20100815
[TBL] [Abstract][Full Text] [Related]
3. Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants.
Kim KH; Kang JY; Kim DH; Park SH; Park SH; Kim D; Park KD; Lee YJ; Jung HC; Pan JG; Ahn T; Yun CH
Drug Metab Dispos; 2011 Jan; 39(1):140-50. PubMed ID: 20962060
[TBL] [Abstract][Full Text] [Related]
4. Generation of the human metabolite piceatannol from the anticancer-preventive agent resveratrol by bacterial cytochrome P450 BM3.
Kim DH; Ahn T; Jung HC; Pan JG; Yun CH
Drug Metab Dispos; 2009 May; 37(5):932-6. PubMed ID: 19237510
[TBL] [Abstract][Full Text] [Related]
5. Desaturation of alkylbenzenes by cytochrome P450(BM3) (CYP102A1).
Whitehouse CJ; Bell SG; Wong LL
Chemistry; 2008; 14(35):10905-8. PubMed ID: 19003834
[No Abstract] [Full Text] [Related]
6. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
[TBL] [Abstract][Full Text] [Related]
7. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
[TBL] [Abstract][Full Text] [Related]
8. Kinetic deuterium isotope effects for 7-alkoxycoumarin O-dealkylation reactions catalyzed by human cytochromes P450 and in liver microsomes. Rate-limiting C-H bond breaking in cytochrome P450 1A2 substrate oxidation.
Kim KH; Isin EM; Yun CH; Kim DH; Guengerich FP
FEBS J; 2006 May; 273(10):2223-31. PubMed ID: 16649998
[TBL] [Abstract][Full Text] [Related]
9. Regioselective hydroxylation of 17β-estradiol by mutants of CYP102A1 from Bacillus megaterium.
Cha GS; Ryu SH; Ahn T; Yun CH
Biotechnol Lett; 2014 Dec; 36(12):2501-6. PubMed ID: 25129047
[TBL] [Abstract][Full Text] [Related]
10. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
Yun CH; Kim KH; Kim DH; Jung HC; Pan JG
Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492
[TBL] [Abstract][Full Text] [Related]
11. Screening of a minimal enriched P450 BM3 mutant library for hydroxylation of cyclic and acyclic alkanes.
Weber E; Seifert A; Antonovici M; Geinitz C; Pleiss J; Urlacher VB
Chem Commun (Camb); 2011 Jan; 47(3):944-6. PubMed ID: 21079837
[TBL] [Abstract][Full Text] [Related]
12. Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs.
Venkataraman H; Verkade-Vreeker MC; Capoferri L; Geerke DP; Vermeulen NP; Commandeur JN
Bioorg Med Chem; 2014 Oct; 22(20):5613-20. PubMed ID: 24999003
[TBL] [Abstract][Full Text] [Related]
13. A highly active single-mutation variant of P450BM3 (CYP102A1).
Whitehouse CJ; Bell SG; Yang W; Yorke JA; Blanford CF; Strong AJ; Morse EJ; Bartlam M; Rao Z; Wong LL
Chembiochem; 2009 Jul; 10(10):1654-6. PubMed ID: 19492389
[TBL] [Abstract][Full Text] [Related]
14. Altering the regioselectivity of the subterminal fatty acid hydroxylase P450 BM-3 towards gamma- and delta-positions.
Dietrich M; Do TA; Schmid RD; Pleiss J; Urlacher VB
J Biotechnol; 2009 Jan; 139(1):115-7. PubMed ID: 18984016
[TBL] [Abstract][Full Text] [Related]
15. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
[TBL] [Abstract][Full Text] [Related]
16. Regioselective hydroxylation of omeprazole enantiomers by bacterial CYP102A1 mutants.
Ryu SH; Park BY; Kim SY; Park SH; Jung HJ; Park M; Park KD; Ahn T; Kang HS; Yun CH
Drug Metab Dispos; 2014 Sep; 42(9):1493-7. PubMed ID: 25008345
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase.
Locuson CW; Ethell BT; Voice M; Lee D; Feenstra KL
Drug Metab Dispos; 2009 Mar; 37(3):457-61. PubMed ID: 19074522
[TBL] [Abstract][Full Text] [Related]
18. Rational design of a minimal and highly enriched CYP102A1 mutant library with improved regio-, stereo- and chemoselectivity.
Seifert A; Vomund S; Grohmann K; Kriening S; Urlacher VB; Laschat S; Pleiss J
Chembiochem; 2009 Mar; 10(5):853-61. PubMed ID: 19222039
[TBL] [Abstract][Full Text] [Related]
19. Control of the stereo-selectivity of styrene epoxidation by cytochrome P450 BM3 using structure-based mutagenesis.
Huang WC; Cullis PM; Raven EL; Roberts GC
Metallomics; 2011 Apr; 3(4):410-6. PubMed ID: 21240430
[TBL] [Abstract][Full Text] [Related]
20. Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11.
Vottero E; Rea V; Lastdrager J; Honing M; Vermeulen NP; Commandeur JN
J Biol Inorg Chem; 2011 Aug; 16(6):899-912. PubMed ID: 21567268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
